HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes

Executive Summary

It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.

You may also be interested in...



US FDA Warning Letter Salvo: No Such Thing As Approved OTC Skin-Lightening Product

The FDA issued warning letters to a dozen companies about marketing OTC skin-lightening products containing hydroquinone. While the agency’s stance was friendlier toward such products when it launched the OTC drug review program 40 years ago, the program has changed, and so have the FDA’s views on hydroquinone.

Hawaii Considers Sweeping Ban On ‘Chemical’ UV Filters, Taking Cues From US FDA

Following Maui County’s example, Hawaii state lawmakers seem intent on limiting OTC sunscreen sales to products formulated with zinc oxide and titanium dioxide, the only active ingredients upheld as GRASE by the US FDA in recent rulemaking overtures.

Appetite In Congress For Adding Supplements To Pre-tax Savings Grows By Another House Bill

Reps. Brendan Boyle and Darin LaHood introduce Dietary Supplement Tax Fairness Ac to amend Internal Revenue Code to include some supplement products as qualified medical expenses.

Related Content

Topics

UsernamePublicRestriction

Register

RS149845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel